WHO R&D Blueprint

novel Coronavirus

COVID-19 Viruses, Reagents and Immune Assays

WHO Working Group
# Table of Contents

TABLE OF CONTENTS ................................................................................................................................. 2  
BACKGROUND .............................................................................................................................................. 3  
TERMS OF REFERENCE ............................................................................................................................... 3  
COMPOSITION.............................................................................................................................................. 3  
  EXPERTS .................................................................................................................................................... 3  
  WHO SECRETARIAT ................................................................................................................................ 6
Background

In response to the current COVID-19 pandemic, the WHO Blueprint team has established an Expert Group focused on COVID-19 viruses, reagents and immune assays. The goal of the group is to advance the development of COVID-19 medical countermeasures (vaccines and immunotherapeutics). This is being achieved by providing a platform to discuss availability of viruses and key reagents, to share data on immune assays and the potential for cross reactivity of SARS-CoV-2 with other coronaviruses.

Terms of Reference

- Discuss the theoretical potential for cross-reactivity between SARS-CoV-2, SARS-CoV-1 and MERS-CoV based on available sequence/modelling data.
- Present data which evaluate cross-reactivity and outline planned experimental approaches that will inform on vaccine and monoclonal antibody selection and thus advance development timelines.
- Obtain an overview on the status of development/availability of SARS-CoV-2 viral isolates and other critical reagents followed by weekly updates.
- Present data on the development of immune assays with an emphasis on ELISA and neutralization, both live virus and pseudovirus.
- Coordinate efforts with other WHO groups focused on COVID-19 control and development of medical countermeasures.

Composition

Experts

Chairs:

Dr. William Dowling, CEPI

The chair has the following responsibilities

- To chair the weekly meetings
- To liaise with the WHO R&D Blueprint
- To review meeting reports and reports from any interim recommendations
- To represent the group at technical meetings as requested

Members:

Ralph Baric, University of North Carolina, USA
Cheryl Bennett, GSAID, Germany
Terms of Reference
WG established on February 2020

Christian Berchot, Global Viral Network, USA
Brooke Bozick, National Institute of Allergy and Infectious Diseases (NIAID-DMID), USA
Karen Bok, National Institute of Allergy and Infectious Diseases (NIAID-VRC), USA
Darin Carroll, Centers for Disease Control and Prevention (CDC), USA
Miles Carroll, Public Health England (PHE), UK
Monalisa Charrerji, Bill and Melinda Gates Foundation (BMGF), USA
Kizzmekia Corbett, National Institute of Allergy and Infectious Diseases (NIAID-VRC), USA
Carolyn Clark, Coalition for Epidemic Preparedness Innovations (CEPI), Norway
Ian Crozier, National Institute of Allergy and Infectious Diseases (NIAID), USA
Inger Damon, Centers for Disease Control and Prevention (CDC), USA
Peter Daszak, EcoHealth Alliance
Marcia DeGrace, National Institute of Allergy and Infectious Diseases (NIAID-DMID), USA
Emmie DeWit, National Institute of Allergy and Infectious Diseases (NIAID-RML), USA
Rafael Delgado Vazquez, Salud Madrid, Spain
Dimiter Dimitrov, Univ. of Pittsburgh, USA
Christian Drosten, Charité - Universitätsmedizin Berlin, Germany
Karl Erlandson, Biomedical Advanced Research and Development Authority (BARDA), USA
Darryl Falzarano, Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO – Intervac), Canada
Clint Florence, National Institute of Allergy and Infectious Diseases (NIAID-DMID), USA
Simon Funnell, Public Health England (PHE), UK
Luc Gagnon (Nexilis)
Susan Gerber, Centers for Disease Control and Prevention (CDC), USA
Volker Gerdts, Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO – Intervac), Canada
Raul Gomez-Roman, Coalition for Epidemic Preparedness Innovations (CEPI), Norway
Barney Graham, National Institute of Allergy and Infectious Diseases (NIAID-VRC), USA
Erica Guthrie, Centers for Disease Control and Prevention (CDC), USA
Bart Haggmans, Erasmus, the Netherlands
Lisa Hensley, National Institute of Allergy and Infectious Diseases (NIAID-IRF), USA
Mike Holbrook, National Institute of Allergy and Infectious Diseases (NIAID-IRF), USA
Paul Hodgson, Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO – Intervac), Canada
Rachel Ireland, Defence Science and Technology (dstl), UK
Lakshmi Jayashanakar, Biomedical Advanced Research and Development Authority (BARDA), USA
Dan Jernigan, Centers for Disease Control and Prevention (CDC), USA
Reed Johnson, National Institute of Allergy and Infectious Diseases (NIAID-IRF), USA
Jacqueline Kirchner, Bill and Melinda Gates Foundation (BMGF), USA
Marion Koopmans, Erasmus, the Netherlands
Florian Krammer, Mt. Sinai, USA
Gerald Kovacs, Biomedical Advanced Research and Development Authority (BARDA), USA
Greg Kulnis (Nexils)
Teresa Lambe, University of Oxford, UK
Janet Lathey, National Institute of Allergy and Infectious Diseases (NIAID-DMID), USA
Joo-Yeon Lee, Korea CDC, Republic of Korea
Steve Lever, Defence Science and Technology (dstl), UK
Hee-Young Lim, Korea CDC, Republic of Korea
Jim Little, Biomedical Advanced Research and Development Authority (BARDA), USA
Karen Makar, Bill and Melinda Gates Foundation (BMGF), USA
Giada Mattiuzzo, National Institute for Biological Standards and Control (NIBSC), UK
John Mellors, University of Pittsburgh, USA
Kayvon Modjarrad, Walter Reed Army Institute of Research (WRAIR), USA
Kaitlyn Morabito, National Institute of Allergy and Infectious Diseases (NIAID-VRC), USA
César Muñoz-Fontela, Bernhard Nocht Institute for Tropical Medicine (BNITM), Germany
Vincent Munster, National Institute of Allergy and Infectious Diseases (NIAID-RML), USA
Scott Napper, Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO – Intervac), Canada
Michelle Nelson, Defence Science and Technology (dstl), UK
Nisreen Okba, Erasmus, The Netherlands
Jae Ouk Kim, IAVI, USA
Mark Page, National Institute for Biological Standards and Control (NIBSC), UK
Gustavo Palacios, United States Army Medical Institute of Infectious Diseases (USAMRIID), USA
Mark Pallansch, Centers for Disease Control and Prevention (CDC), USA
Jo Prior, Defence Science and Technology (dstl), UK
Nicola Rose, National Institute for Biological Standards and Control (NIBSC), UK
Connie Schmaljohn, National Institute of Allergy and Infectious Diseases (NIAID-IRF), USA
Barbara Schnierle, PEI, Germany
Amy Shurtleff, Coalition for Epidemic Preparedness Innovations (CEPI), Norway
Ashley Smith, Biomedical Advanced Research and Development Authority (BARDA), USA
Manki Song, IAVI, USA
Erik Stemmy, National Institute of Allergy and Infectious Diseases (NIAID-DMID), USA
Natalie Thornburg, Centers for Disease Control and Prevention (CDC), USA
Tracy Thue, Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO – Intervac), Canada
Julia Tree, Public Health England (PHE), UK
Sylvie Van Der Werf, Institut Pasteur, France
Seshadri Vasan, The Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia
David Vaughn, Bill and Melinda Gates Foundation (BMGF), USA
Linfa Wang, Duke-NUS, Singapore
Patrick Wilson, University of Chicago, USA
Larry Wolfrain, National Institute of Allergy and Infectious Diseases (NIAID), USA
Tianlei Ying, Fudan University, China
Shi Zengli, Wuhan Institute of Virology, China
WHO Secretariat
Ana Maria Henao-Restrepo, Pierre Gsell, Ximena Riveros, Alejandro Costa, Vaseeharan Sathiyamoorthy, Mark Perkins, Soumya Swaminathan.